Phase 2A study of Radspherin
Latest Information Update: 20 Feb 2023
At a glance
- Drugs Radspherin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Feb 2023 According to Oncoinvent media release, the company anticipates to publish 15-month and 18-month progression free survival data in the same group of patients at conferences later this year.
- 10 Feb 2023 According to Oncoinvent media release, inclusion for phase IIA has been initiated.
- 25 Aug 2022 According to an Oncoinvent media release, the study has been conducted at two sites, the Radium Hospital in Oslo Norway and at the Uppsala University Hospital in Uppsala Sweden.